Fierce Pharma

MAY 24, 2024

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic

Patients 291

Patients 291

MedCity News

MAY 24, 2024

Allegheny Health Network rolled out a large language model designed exclusively for use by its staff members. You can think of the tool as the health system’s own version of Chat-GPT, said Ashis Barad, AHN’s chief digital and information officer. The post Why Allegheny Health Network Created Its Own Chat-GPT For Employees appeared first on MedCity News.

Networking 118

Networking Healthcare Healthcare 118

Clarivate

MAY 21, 2024

We have released the first version of the Clarivate Academic AI Platform, serving our suite of AI-powered Research Assistants. Discover how it is going to help address the needs of students, researchers and librarians for trusted AI. At Clarivate TM , we understand the transformative power of artificial intelligence (AI) in the academic realm and the imperative to introduce AI thoughtfully and responsibly into research, teaching and learning environments.

Government 128

Government Ethics Management Specialization 128

Pharmaceutical Commerce

MAY 23, 2024

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

105

105

Advertisement

Distribution

pharmaphorum

MAY 23, 2024

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is prepared to go to market on its own.

Leads 88

Leads Marketing 88

Fierce Pharma

MAY 23, 2024

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | With prior approvals in melanoma, Bristol Myers Squibb and Iovance are now showcasing early clinical data for their novel combinations in small first-line melanoma trials.

272

272

PharmaTimes

MAY 23, 2024

High-grade gliomas are rare, malignant tumours which account for up to 12% of all childhood brain tumours

124

124

Scott Burrows

MAY 21, 2024

In the world of motivational speaking, stories of triumph over adversity are not uncommon. But for me, the narrative goes beyond inspiration—it’s about embodying the very principles of vision, mindset, and grit that have shaped my journey. At the age of 19, a car accident left me with a broken neck and a daunting diagnosis of quadriplegia. But from the confines of a wheelchair, I refused to let my circumstances define me.

Management 98

Management Marketing 98

pharmaphorum

MAY 22, 2024

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.

96

96

Fierce Pharma

MAY 23, 2024

Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the industry has rarely seen good news coming from the White House. | Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma's pricing, the industry has rarely seen good news coming from the White House.

Pharma 269

Pharma Medical Pharmaceutical 269

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

MAY 21, 2024

Employers need healthcare data in order to make decisions, but the data isn’t always easy to get, experts said on a panel at MedCity INVEST. The post Why Healthcare Data Is Vital for Employers appeared first on MedCity News.

Healthcare 120

Healthcare Healthcare 120

PharmaTech

MAY 22, 2024

The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.

Medical 104

Medical Medicine Patients 104

Pharmaceutical Technology

MAY 23, 2024

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.

103

103

pharmaphorum

MAY 22, 2024

A think tank set up by former UK Prime Minister Tony Blair has called for the formation of a public-private trust that could oversee the sharing of anonymised patient data with trusted researchers.

Patients 95

Patients 95

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

Fierce Pharma

MAY 21, 2024

A decade ago, with AstraZeneca in decline and some investors urging the drugmaker to sell out to Pfizer, new CEO Pascal Soriot presented an audacious plan to hike revenue to $45 billion by 2023. | After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030.

265

265

MedCity News

MAY 23, 2024

Fem Therapeutics won the audience choice award in the Canadian PItch contest at MedCity INVEST in Chicago this week. It competed with Reach Orthopaedics , PragmaClin Research, and OPTT Health. The post Canadian Women’s Health Medtech Startup Wins Over Audience at MedCity INVEST appeared first on MedCity News.

104

104

Pharmaceutical Commerce

MAY 23, 2024

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.

Manufacturing 105

Manufacturing Pharmaceutical 105

Pharmaceutical Technology

MAY 23, 2024

Merck KGaA’s MilliporeSigma has entered a definitive agreement for the acquisition of Mirus Bio in a deal totaling $600m (€500m).

101

101

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

MAY 21, 2024

FDA is asking artificial intelligence teams to develop a digital endpoint tool to study freezing of gait, a symptom of Parkinson’s that can have a serious impact on patients.

Competition 95

Competition FDA Patients 95

Fierce Pharma

MAY 22, 2024

Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.

Pharmaceutical 252

Pharmaceutical 252

MedCity News

MAY 27, 2024

Justin Brueck, vice president of innovation and research at Endeavor Health, shared three main reasons that technology pilots end up being unsuccessful at health systems. The post The Top 3 Reasons That Hospitals’ Tech Pilots Fail appeared first on MedCity News.

81

81

PharmaTimes

MAY 24, 2024

The lifelong autoimmune disease affects more than 150,000 people living in the UK

Doctors 106

Doctors Training Management 106

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

European Pharmaceutical Review

MAY 23, 2024

A paper has reported a multi-material ink-jet 3D printing (MM-IJ3DP)-based method that could enable tailored drug release profiles of personalised pharmaceutical tablets during manufacturing. While biocompatible water-soluble polymers as excipients, have “been recently explored to produce gels [they have not been investigated] as a water-soluble excipient”, according to the paper.

Manufacturing 74

Manufacturing Pharmaceutical manufacturing Medicine Pharmaceutical 74

pharmaphorum

MAY 24, 2024

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy. The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), which will be reported at the ASCO congress next week.

Patients 87

Patients 87

Fierce Pharma

MAY 22, 2024

The more than 53,000 women in the U.S. | The more than 53,000 women in the U.S. who have filed injury lawsuits against Johnson & Johnson have added ammunition for their claims as new research indicates there is an association between long-term use of talcum-based powders and an increased risk of developing ovarian cancer.

250

250

MedCity News

MAY 21, 2024

The NIH’s SEED office formed to help startups leverage government’s funding programs. Chris Sasiela, director of the SEED office, discussed these programs during the MedCity News INVEST Conference in Chicago. The post 5 Things to Know About How NIH’s SEED Can Help Life Science Startups Grow appeared first on MedCity News.

Biopharma 102

Biopharma 102

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PharmaVoice

MAY 21, 2024

These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.

105

105

Pharmaceutical Commerce

MAY 21, 2024

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the pharma industry.

Pharma 81

Pharma 81

pharmaphorum

MAY 21, 2024

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

98

98

Fierce Pharma

MAY 22, 2024

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. | Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer.

250

250

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management